Search | Clinical Trials Finder

Conditions: Crohn Disease
Interventions: CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab; Device · Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 30 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Hodgkin Lymphoma, Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
Interventions: CliniMACS, Stem cell transplantation, Fludarabine, Thioplex®, L-phenylalanine mustard, Mycophenolate mofetil, Rituxan™, Alemtuzumab, Cyclophosphamide, Anti-thymocyte globulin (Rabbit), G-CSF, Muromonab; Device · Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Neuroblastoma, Lymphoma, High-risk Tumor
Interventions: CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A, Busulfan, Melphalan, GM-CSF, Bendamustine, Etoposide, Cytarabine, Carboplatin, Haploidentical natural killer cell infusion, G-CSF, Etoposide phosphate, CliniMACS; Biological · Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions: Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide, Fludarabine, G-CSF, Melphalan, Mesna, Rituximab, Tacrolimus, Thiotepa, HPC,A Infusion, CliniMACS, Sirolimus; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Acute Myelogenous Leukemia
Interventions: IL-15; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions: Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes; Biological
Lead sponsor: Jessie L. Alexander; Other
Eligibility: 1 Month to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Palo Alto, California

Conditions: Graft Vs Host Disease, Graft-versus-host-disease
Interventions: CliniMacs®; Device
Lead sponsor: Christopher Dvorak; Other
Eligibility: Up to 30 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2035
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Primary Immunodeficiency, PID
Interventions: CD3/CD19 neg allogeneic BMT; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 10 Years to 45 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Interventions: DuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy); Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Westwood, Kansas

Conditions: Hematologic Disorders
Interventions: Miltenyi CliniMACS® CD34 Reagent System; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Lymphomas, Bone Marrow Failure, Hemoglobinopathy, Immune Deficiency, Osteopetrosis, Cytopenias, Leukocyte Disorders, Anemia Due to Intrinsic Red Cell Abnormality
Interventions: CD34+ enriched, T Cell Depleted donor stem cell product; Biological
Lead sponsor: Christopher Dvorak; Other
Eligibility: 2 Months to 30 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Allogeneic Hematopoietic Cell Transplantation
Interventions: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
Interventions: Fludarabine, Cytarabine, Cellular Infusions, Total Body Irradiation, Cyclophosphamide, Bortezomib, Rituximab, Plasmapheresis; Drug · Device · Radiation + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Lymphoma
Interventions: Total Lymphoid Irradiation, Fludarabine, Cyclophosphamide, Thiotepa, Melphalan, HPC,A Infusion, TC-NK Infusion, G-CSF, Mesna, CliniMACS, Mycophenolate mofetil; Radiation · Drug · Biological + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Adenovirus Infection
Interventions: Adenovirus Specific T lymphocytes; Biological
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Up to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Intestinal Transplantation
Interventions: Cell Therapy; Biological
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: SCID
Interventions: Busulfan, Cell processing for TCRαβ+/CD19+ depletion; Drug · Device
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 0 Years to 2 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: Severe Combined Immunodeficiency
Interventions: AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Months and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2038
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Myeloid Leukemia
Interventions: ALT-803; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Acute Myelogenous Leukemia
Interventions: CD3-/CD19- natural killer cells, CD3-CD56+ natural killer cells, CliniMACS® CD3 and CD19 Reagent System, CliniMACS® CD56 Reagent System, Cyclophosphamide, Fludarabine, Aldesleukin; Biological · Device · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • St Louis, Missouri

Conditions: Hematologic Malignancies
Interventions: CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus; Device · Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
Interventions: CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes, Standard of Care Chemotherapy; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 79 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Severe Combined Immunodeficiency
Interventions: Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine, Thiotepa, CliniMACS, Donor Lymphocyte Infusion; Drug · Device · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Months and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Neuroblastoma
Interventions: Carboplatin, Etoposide, Melphalan, Stem Cell Infusion, ClinicMACS; Drug · Procedure · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders

Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant

TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders

Treatment of Sickle Cell Anemia With Stem Cell Transplant

Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections

Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation

Conditioning SCID Infants Diagnosed Early

Autologous Gene Therapy for Artemis-Deficient SCID

QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma